Rectum rhabdomyosarcoma

Summary

Rectum rhabdomyosarcoma (MONDO:0002853) is a disease. A subtype of rectum sarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	rectum rhabdomyosarcoma
Mondo ID	MONDO:0002853
DOID	DOID:4053
NCIT	C5627
UMLS	C1335687
MedGen	235532
GARD	0023271
Anatomy (UBERON)	UBERON:0001052
Is cancer (heuristic)	no

Also known as: rectal rhabdomyosarcoma · rectum rhabdomyosarcoma (disease) · rhabdomyosarcoma (disease) of rectum · rhabdomyosarcoma of rectum · rhabdomyosarcoma of the rectum

Disease family

This is a subtype of rectum sarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › sarcoma › rectum sarcoma › rectum rhabdomyosarcoma

Related subtypes (3): anus sarcoma, rectum leiomyosarcoma, rectum Kaposi sarcoma

Subtypes (1): anus rhabdomyosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.